From Reflux Esophagitis to Esophageal Adenocarcinoma

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Reflux esophagitis causes Barrett's metaplasia, an abnormal esophageal mucosa predisposed to adenocarcinoma. Medical therapy for reflux esophagitis focuses on decreasing gastric acid production with proton pump inhibitors. We have reported that reflux esophagitis in a rat model develops from a cytokine-mediated inflammatory injury, not from a caustic chemical (acid) injury. In this model, refluxed acid and bile stimulate the release of inflammatory cytokines from esophageal squamous cells, recruiting lymphocytes first to the submucosa and later to the luminal surface. Emerging studies on acute reflux esophagitis in humans support this new concept, suggesting that reflux-induced cytokine release may be a future target for medical therapies. Sometimes, reflux esophagitis heals with Barrett's metaplasia, a process facilitated by reflux-related nitric oxide (NO) production and Sonic Hedgehog (Hh) secretion by squamous cells. We have shown that NO reduces expression of genes that promote a squamous cell phenotype, while Hh signaling induces genes that mediate the development of the columnar cell phenotypes of Barrett's metaplasia. Agents targeting esophageal NO production or Hh signaling conceivably could prevent the development of Barrett's esophagus. Persistent reflux promotes cancer in Barrett's metaplasia. We have reported that acid and bile salts induce DNA damage in Barrett's cells. Bile salts also cause NF-κB activation in Barrett's cells, enabling them to resist apoptosis in the setting of DNA damage and likely contributing to carcinogenesis. Oral treatment with ursodeoxycholic acid prevents the esophageal DNA damage and NF-κB activation induced by toxic bile acids. Altering bile acid composition might be another approach to cancer prevention.

Original languageEnglish (US)
Pages (from-to)483-490
Number of pages8
JournalDigestive Diseases
Volume34
Issue number5
DOIs
StatePublished - Jun 1 2016

Fingerprint

Peptic Esophagitis
Barrett Esophagus
Bile Acids and Salts
Adenocarcinoma
Hedgehogs
DNA Damage
Nitric Oxide
Epithelial Cells
Cytokines
Phenotype
Ursodeoxycholic Acid
Caustics
Proton Pump Inhibitors
Poisons
Gastric Acid
Wounds and Injuries
Neoplasms
Carcinogenesis
Lymphocytes
Apoptosis

Keywords

  • Barrett's metaplasia
  • Cytokine
  • Nitric oxide
  • Sonic Hedgehog
  • Ursodeoxycholic acid

ASJC Scopus subject areas

  • Gastroenterology

Cite this

From Reflux Esophagitis to Esophageal Adenocarcinoma. / Souza, Rhonda F.

In: Digestive Diseases, Vol. 34, No. 5, 01.06.2016, p. 483-490.

Research output: Contribution to journalArticle

@article{2b67a204be5547cdafe9e87b11634788,
title = "From Reflux Esophagitis to Esophageal Adenocarcinoma",
abstract = "Reflux esophagitis causes Barrett's metaplasia, an abnormal esophageal mucosa predisposed to adenocarcinoma. Medical therapy for reflux esophagitis focuses on decreasing gastric acid production with proton pump inhibitors. We have reported that reflux esophagitis in a rat model develops from a cytokine-mediated inflammatory injury, not from a caustic chemical (acid) injury. In this model, refluxed acid and bile stimulate the release of inflammatory cytokines from esophageal squamous cells, recruiting lymphocytes first to the submucosa and later to the luminal surface. Emerging studies on acute reflux esophagitis in humans support this new concept, suggesting that reflux-induced cytokine release may be a future target for medical therapies. Sometimes, reflux esophagitis heals with Barrett's metaplasia, a process facilitated by reflux-related nitric oxide (NO) production and Sonic Hedgehog (Hh) secretion by squamous cells. We have shown that NO reduces expression of genes that promote a squamous cell phenotype, while Hh signaling induces genes that mediate the development of the columnar cell phenotypes of Barrett's metaplasia. Agents targeting esophageal NO production or Hh signaling conceivably could prevent the development of Barrett's esophagus. Persistent reflux promotes cancer in Barrett's metaplasia. We have reported that acid and bile salts induce DNA damage in Barrett's cells. Bile salts also cause NF-κB activation in Barrett's cells, enabling them to resist apoptosis in the setting of DNA damage and likely contributing to carcinogenesis. Oral treatment with ursodeoxycholic acid prevents the esophageal DNA damage and NF-κB activation induced by toxic bile acids. Altering bile acid composition might be another approach to cancer prevention.",
keywords = "Barrett's metaplasia, Cytokine, Nitric oxide, Sonic Hedgehog, Ursodeoxycholic acid",
author = "Souza, {Rhonda F.}",
year = "2016",
month = "6",
day = "1",
doi = "10.1159/000445225",
language = "English (US)",
volume = "34",
pages = "483--490",
journal = "Digestive Diseases",
issn = "0257-2753",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - From Reflux Esophagitis to Esophageal Adenocarcinoma

AU - Souza, Rhonda F.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Reflux esophagitis causes Barrett's metaplasia, an abnormal esophageal mucosa predisposed to adenocarcinoma. Medical therapy for reflux esophagitis focuses on decreasing gastric acid production with proton pump inhibitors. We have reported that reflux esophagitis in a rat model develops from a cytokine-mediated inflammatory injury, not from a caustic chemical (acid) injury. In this model, refluxed acid and bile stimulate the release of inflammatory cytokines from esophageal squamous cells, recruiting lymphocytes first to the submucosa and later to the luminal surface. Emerging studies on acute reflux esophagitis in humans support this new concept, suggesting that reflux-induced cytokine release may be a future target for medical therapies. Sometimes, reflux esophagitis heals with Barrett's metaplasia, a process facilitated by reflux-related nitric oxide (NO) production and Sonic Hedgehog (Hh) secretion by squamous cells. We have shown that NO reduces expression of genes that promote a squamous cell phenotype, while Hh signaling induces genes that mediate the development of the columnar cell phenotypes of Barrett's metaplasia. Agents targeting esophageal NO production or Hh signaling conceivably could prevent the development of Barrett's esophagus. Persistent reflux promotes cancer in Barrett's metaplasia. We have reported that acid and bile salts induce DNA damage in Barrett's cells. Bile salts also cause NF-κB activation in Barrett's cells, enabling them to resist apoptosis in the setting of DNA damage and likely contributing to carcinogenesis. Oral treatment with ursodeoxycholic acid prevents the esophageal DNA damage and NF-κB activation induced by toxic bile acids. Altering bile acid composition might be another approach to cancer prevention.

AB - Reflux esophagitis causes Barrett's metaplasia, an abnormal esophageal mucosa predisposed to adenocarcinoma. Medical therapy for reflux esophagitis focuses on decreasing gastric acid production with proton pump inhibitors. We have reported that reflux esophagitis in a rat model develops from a cytokine-mediated inflammatory injury, not from a caustic chemical (acid) injury. In this model, refluxed acid and bile stimulate the release of inflammatory cytokines from esophageal squamous cells, recruiting lymphocytes first to the submucosa and later to the luminal surface. Emerging studies on acute reflux esophagitis in humans support this new concept, suggesting that reflux-induced cytokine release may be a future target for medical therapies. Sometimes, reflux esophagitis heals with Barrett's metaplasia, a process facilitated by reflux-related nitric oxide (NO) production and Sonic Hedgehog (Hh) secretion by squamous cells. We have shown that NO reduces expression of genes that promote a squamous cell phenotype, while Hh signaling induces genes that mediate the development of the columnar cell phenotypes of Barrett's metaplasia. Agents targeting esophageal NO production or Hh signaling conceivably could prevent the development of Barrett's esophagus. Persistent reflux promotes cancer in Barrett's metaplasia. We have reported that acid and bile salts induce DNA damage in Barrett's cells. Bile salts also cause NF-κB activation in Barrett's cells, enabling them to resist apoptosis in the setting of DNA damage and likely contributing to carcinogenesis. Oral treatment with ursodeoxycholic acid prevents the esophageal DNA damage and NF-κB activation induced by toxic bile acids. Altering bile acid composition might be another approach to cancer prevention.

KW - Barrett's metaplasia

KW - Cytokine

KW - Nitric oxide

KW - Sonic Hedgehog

KW - Ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=84976274960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976274960&partnerID=8YFLogxK

U2 - 10.1159/000445225

DO - 10.1159/000445225

M3 - Article

C2 - 27331918

AN - SCOPUS:84976274960

VL - 34

SP - 483

EP - 490

JO - Digestive Diseases

JF - Digestive Diseases

SN - 0257-2753

IS - 5

ER -